“…Irinotecan-TACE is generally well tolerated with serious adverse events (AEs) experienced in about 0–10% of patients [ 11 , 12 , 13 , 14 , 15 , 16 , 17 ]. However, grade 1 and 2 post-embolization syndrome (PES) after a treatment session is a common occurrence (10–60%) [ 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 ]. Although there are recommendations regarding treatment plans [ 25 , 26 ], such as to perform at least two sessions for unilobar and four sessions for bilobar disease and regarding technical considerations like the use of opioids, intra-arterial anesthetic, and antiemetics, recent literature has highlighted the lack of standardized technical protocols [ 11 ].…”